[go: up one dir, main page]

NO975561L - Kalsiumkanalantagonister - Google Patents

Kalsiumkanalantagonister

Info

Publication number
NO975561L
NO975561L NO975561A NO975561A NO975561L NO 975561 L NO975561 L NO 975561L NO 975561 A NO975561 A NO 975561A NO 975561 A NO975561 A NO 975561A NO 975561 L NO975561 L NO 975561L
Authority
NO
Norway
Prior art keywords
calcium channel
channel antagonists
alkyl
phenyl
rog
Prior art date
Application number
NO975561A
Other languages
English (en)
Other versions
NO975561D0 (no
Inventor
Marlene L Cohen
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO975561L publication Critical patent/NO975561L/no
Publication of NO975561D0 publication Critical patent/NO975561D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Det er beskrevet en fremgangsmåte for å antagonisere eller blokkere kalsiumkanaler i vaskulært vev som omfatter administrering til et dyr som har behov for dette av en farmasøytisk effektiv mengde av en forbindelse med formel (I). hvor Rog R3 uavhengig av hverandre er hydrogen, CCalkyl, -CO-(CCalkyl), eller -CHAr, -CO-Ar, hvor Ar er fenyl eller substituert fenyl; Rer valgt fra gruppen bestående pyrrolidin, heksametylenimino og piperidino; eller et farmasøytisk akseptabelt salt derav.
NO975561A 1995-06-07 1997-12-02 Kalsiumkanalantagonister NO975561D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/485,406 US5840747A (en) 1995-06-07 1995-06-07 Calcium channel antagonists
PCT/US1996/009162 WO1996040134A1 (en) 1995-06-07 1996-06-04 Calcium channel antagonists

Publications (2)

Publication Number Publication Date
NO975561L true NO975561L (no) 1997-12-02
NO975561D0 NO975561D0 (no) 1997-12-02

Family

ID=23928032

Family Applications (1)

Application Number Title Priority Date Filing Date
NO975561A NO975561D0 (no) 1995-06-07 1997-12-02 Kalsiumkanalantagonister

Country Status (21)

Country Link
US (1) US5840747A (no)
EP (1) EP0831822B1 (no)
JP (1) JPH11506788A (no)
KR (1) KR19990022499A (no)
CN (1) CN1193274A (no)
AT (1) ATE252902T1 (no)
AU (1) AU714403B2 (no)
CA (1) CA2223711A1 (no)
CZ (1) CZ288546B6 (no)
DE (1) DE69630523T2 (no)
EA (1) EA001928B1 (no)
ES (1) ES2210373T3 (no)
HU (1) HUP9900916A3 (no)
IL (1) IL122459A (no)
MX (1) MX9709468A (no)
NO (1) NO975561D0 (no)
NZ (1) NZ310178A (no)
PL (1) PL183998B1 (no)
RO (1) RO116344B1 (no)
UA (1) UA43895C2 (no)
WO (1) WO1996040134A1 (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008232A (en) * 1997-08-20 1999-12-28 Eli Lilly And Company Methods for preventing headaches
AU7896100A (en) * 1999-10-14 2001-04-23 Endorecherche Inc. Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance
EP1113007A1 (en) 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5441965A (en) * 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting thrombin
US5447941A (en) * 1993-12-21 1995-09-05 Eli Lilly And Company Methods of inhibiting pulmonary hypertensive diseases with raloxifene and related benzothiophenes
US6562862B1 (en) * 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
US5532254A (en) * 1995-06-07 1996-07-02 Eli Lilly And Company Modulation of calcium channels using benzothiophenes

Also Published As

Publication number Publication date
AU714403B2 (en) 2000-01-06
MX9709468A (es) 1998-04-30
IL122459A (en) 2001-05-20
AU6091996A (en) 1996-12-30
EA199800033A1 (ru) 1998-06-25
CZ382897A3 (cs) 1999-01-13
JPH11506788A (ja) 1999-06-15
RO116344B1 (ro) 2001-01-30
DE69630523D1 (de) 2003-12-04
IL122459A0 (en) 1998-06-15
ATE252902T1 (de) 2003-11-15
UA43895C2 (uk) 2002-01-15
HUP9900916A3 (en) 1999-11-29
DE69630523T2 (de) 2004-08-12
EP0831822A1 (en) 1998-04-01
EP0831822B1 (en) 2003-10-29
PL324086A1 (en) 1998-05-11
ES2210373T3 (es) 2004-07-01
HUP9900916A2 (hu) 1999-09-28
NO975561D0 (no) 1997-12-02
NZ310178A (en) 2000-06-23
EA001928B1 (ru) 2001-10-22
WO1996040134A1 (en) 1996-12-19
KR19990022499A (ko) 1999-03-25
CA2223711A1 (en) 1996-12-19
EP0831822A4 (en) 2001-12-19
CZ288546B6 (cs) 2001-07-11
PL183998B1 (pl) 2002-08-30
US5840747A (en) 1998-11-24
CN1193274A (zh) 1998-09-16

Similar Documents

Publication Publication Date Title
NO973635L (no) Fremgangsmåte for hemming av celle-celle adhesjon
DK0652005T3 (da) Fremgangsmåder til inhibering af endometriose
NO996108L (no) 9-oksinerytromycinderivater
NO944927L (no) Fremgangsmåte for inhibering av pulmonar hypertensiv sykdom
DK0651999T3 (da) Fremgangsmåder til inhibering af livmoderfibrose
DK0659417T3 (da) Fremgangsmåder til inhibering af dysfunktionel blødning fra livmoderen
MX9701325A (es) Metodos para inhibir la mucositis ulcerativa.
MX9701329A (es) Metodos para la inhibicion de la replicacion viral.
UA32427C2 (uk) Застосування бензотіофенів або їх фармацевтично прийнятних солей або сольватів для інгібування ангіогенезу і/або ангіогенних захворювань
NO944926L (no) Fremgangsmåter for å inhibere myeloperoksidaseaktivitet
NO944933L (no) Fremgangsmåte for å inhibere sykdomstilstander i brystet
NO944924L (no) Fremgangsmåter for inhibering av Turner's syndrom
NO944931L (no) Anvendelse av 2-fenyl-3-aroylbenzotiofener for inhibering av tidlig seksuell modenhet
NO975580L (no) Fremgangsmåte for å inhibere melanom
NO970786L (no) Fremgangsmåte for hemming av benprotesedegradering
NO975738L (no) Modulering av kalsiumkanaler
NO973367L (no) Fremgangsmåte for å inhibere miljömessige östrogen
NO973609L (no) Fremgangsmåte for å inhibere effektene av IL-6
NO975561L (no) Kalsiumkanalantagonister
NO981578L (no) FremgangsmÕte for hemming av plasminogenaktivatorhemmer I
NO20000750L (no) FremgangsmÕte for Õ redusere blodplatetall
MX9701333A (es) Metodos para inhibir el daño neuronal.
NO971794L (no) Fremgangsmåte for hemming av tilstander forbundet med bradykinin
NO973103L (no) Fremgangsmåte for inhibering av veksthormoneffekter
NO944909L (no) Fremgangsmåter for inhibering av mannlig infertilitet

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application